Kwality Pharmaceuticals Limited (KPL) has completed the EU GMP Inspection for its Cephalosporin and Oncology manufacturing unit II at Himachal Pradesh. The GMP inspection of the site was conducted between April 18 to April 22, 2023.

At the end of the inspection, it is concluded that the Quality system followed at the Himachal site is compliant with the EU GMP Standards. Kwality facilities are designed to meet the highest global regulatory standards, and as the other global inspections also come through, it will have all the necessary approvals to cater to global players.

The EU- GMP approval is an important stepping stone in the journey of the company and will help to expand and strengthen its presence in more regulated markets and will enable us to serve patients across the globe. It allows the company to market its products in all the twenty-seven member countries of the EU.

The EU-GMP Approval is the result of stringent quality and compliance norms followed at Kwality Pharma across all departments. Over the years the company has seen a rise in the export business, which will get a further boost once EU operations begin.

This approval reaffirms the company's focussed efforts to maintain the GMP status up to the standards of global regulatory authorities.